Contrasting Aspire Biopharma (ASBP) and Its Peers

Aspire Biopharma (NASDAQ:ASBP) is one of 617 publicly-traded companies in the “MED – BIOMED/GENE” industry, but how does it compare to its competitors? We will compare Aspire Biopharma to related businesses based on the strength of its earnings, profitability, analyst recommendations, institutional ownership, dividends, valuation and risk.

Institutional & Insider Ownership

19.2% of Aspire Biopharma shares are held by institutional investors. Comparatively, 51.2% of shares of all “MED – BIOMED/GENE” companies are held by institutional investors. 25.8% of Aspire Biopharma shares are held by insiders. Comparatively, 13.6% of shares of all “MED – BIOMED/GENE” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Volatility & Risk

Aspire Biopharma has a beta of 0.76, meaning that its share price is 24% less volatile than the S&P 500. Comparatively, Aspire Biopharma’s competitors have a beta of 0.97, meaning that their average share price is 3% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings for Aspire Biopharma and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aspire Biopharma	1	0	0	0	1.00
Aspire Biopharma Competitors	5916	12229	37690	1173	2.60

As a group, “MED – BIOMED/GENE” companies have a potential upside of 49.70%. Given Aspire Biopharma’s competitors stronger consensus rating and higher possible upside, analysts plainly believe Aspire Biopharma has less favorable growth aspects than its competitors.

Earnings and Valuation

This table compares Aspire Biopharma and its competitors revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Aspire Biopharma	N/A	-$12.54 million	-0.21
Aspire Biopharma Competitors	$968.87 million	-$45.60 million	12.83

Aspire Biopharma’s competitors have higher revenue, but lower earnings than Aspire Biopharma. Aspire Biopharma is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Aspire Biopharma and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aspire Biopharma	N/A	N/A	-1,052.55%
Aspire Biopharma Competitors	-1,425.99%	-589.65%	-28.81%

Summary

Aspire Biopharma competitors beat Aspire Biopharma on 9 of the 13 factors compared.

About Aspire Biopharma

Aspire Biopharma Holdings, Inc., early-stage biopharmaceutical company, engages in developing and marketing of disruptive technology for delivery mechanisms for do no harm drugs in the United States. The company provides Sublingual Aspirin Product, which addresses cardiology emergencies and pain management. It develops formulation for a sublingually administered melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide, as well as formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and several other classes of drugs. The company was founded in 2021 and is based in Humacao, Puerto Rico.